PF0 and AINMF Related Headlines
Go Back- NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
- NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
- NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
- NetraMark director Lawrence Guy resigns from board
- NetraMark Announces Change To Board Of Directors
- NetraMark names Dr. Panteli Theocharous fractional chief medical officer
- NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
- NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
- NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
- Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
- Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
- NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
- NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
- NetraMark signs contract to analyze phase 2 depression trial data
- NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
- NetraMark completes $3.5 million private placement financing
- NetraMark Closes Final Tranche of $3.5 Million Private Placement
- Netramark Announces Uplisting to Toronto Stock Exchange
- NetraMark Strengthens Board Of Directors
- NetraMark closes first tranche of private placement for $3.1 million
- NetraMark Closes First Tranche of Private Placement
- NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
- NetraMark raises up to $3.5 million in private placement
- NetraMark Announces Private Placement Financing
- NetraMark Delivers Transformational Quarter Of Execution
- NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression
- NetraMark Achieves Major FDA Milestone
- NetraMark wins phase 3 clinical trial contract from global biopharma
- NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company
- NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
- NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
- Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
- NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference
- NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
- NetraMark appoints Jan Sedway as senior VP of clinical science
- NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership
- NetraMark signs contract with Asklepion for pediatric cardiac study analysis
- Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
- NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
- NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity
- NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
- NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
PF0 and AINMF Related Press Releases
Go Back- NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026
- NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
- NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum
- NetraMark Announces Change To Board Of Directors
- NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI
- NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
- NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
- Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
- Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain
- NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset
- NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference
- NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
- NetraMark Closes Final Tranche of $3.5 Million Private Placement
- Netramark Announces Uplisting to Toronto Stock Exchange
- NetraMark Strengthens Board Of Directors
- NetraMark Closes First Tranche of Private Placement
- NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
- NetraMark Announces Private Placement Financing
- NetraMark Delivers Transformational Quarter Of Execution
- NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression
- NetraMark Achieves Major FDA Milestone
- NetraMark Continues Expansion Into Phase 3 Programs With Contract From Global Biopharmaceutical Company
- NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio
- NetraMark Signs Four New Contracts With a Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
- Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights
- NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference
- NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
- NetraMark Appoints Jan Sedway as Senior Vice President of Clinical Science to Accelerate Growth and Market Leadership
- Asklepion Pharmaceuticals Signs Contract to Utilize NetraMark Technology in Phase III Pediatric Cardiac Study
- NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
- NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity
- NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
- NetraMark's AI Significantly Outperforms ChatGPT, DeepSeek and Traditional Machine Learning in Clinical Trial Subpopulation Discovery, Offers New Path for Trial Success
